Insider Buying: Athenex Inc (ATNX) Director Purchases 30,000 Shares of Stock
Athenex Inc (NASDAQ:ATNX) Director Manson Fok purchased 30,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was purchased at an average cost of $14.31 per share, for a total transaction of $429,300.00. Following the completion of the acquisition, the director now directly owns 1,799,609 shares of the company’s stock, valued at approximately $25,752,404.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Athenex Inc (ATNX) opened at $14.12 on Friday. Athenex Inc has a 1-year low of $11.21 and a 1-year high of $20.79.
Athenex (NASDAQ:ATNX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.30) earnings per share for the quarter. sell-side analysts forecast that Athenex Inc will post -2.3 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC purchased a new stake in shares of Athenex during the fourth quarter valued at $161,000. California State Teachers Retirement System purchased a new stake in shares of Athenex during the third quarter valued at $198,000. Bank of New York Mellon Corp purchased a new stake in shares of Athenex during the second quarter valued at $240,000. Tudor Investment Corp ET AL purchased a new stake in shares of Athenex during the second quarter valued at $320,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Athenex during the fourth quarter valued at $333,000. 2.69% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Insider Buying: Athenex Inc (ATNX) Director Purchases 30,000 Shares of Stock” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/11/insider-buying-athenex-inc-atnx-director-purchases-30000-shares-of-stock.html.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.